These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37580710)

  • 1. CRISPR-Cas9 identifies growth-related subtypes of glioblastoma with therapeutical significance through cell line knockdown.
    Zhao N; Weng S; Liu Z; Xu H; Ren Y; Guo C; Liu L; Zhang Z; Ji Y; Han X
    BMC Cancer; 2023 Aug; 23(1):749. PubMed ID: 37580710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and prognostic significance of TCTN1 in human glioblastoma.
    Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
    J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
    Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establish six-gene prognostic model for glioblastoma based on multi-omics data of TCGA database.
    Lei CG; Jia XY; Sun WJ
    Yi Chuan; 2021 Jul; 43(7):665-679. PubMed ID: 34284982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
    Lehrer S; Rheinstein PH; Rosenzweig KE
    Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
    Li L; Huang Y; Gao Y; Shi T; Xu Y; Li H; Hyytiäinen M; Keski-Oja J; Jiang Q; Hu Y; Du Z
    BMC Cancer; 2018 Dec; 18(1):1215. PubMed ID: 30514230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
    Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
    PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma.
    Yu W; Ma Y; Hou W; Wang F; Cheng W; Qiu F; Wu P; Zhang G
    Front Immunol; 2021; 12():706936. PubMed ID: 34899682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
    Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA sequencing and Immunohistochemistry Reveal
    Esteve-Codina A; Alameda F; Carrato C; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Dabad M; Tortosa A; Del Barco S; Capellades J; Puig J; Gallego O; Pujol T; Oleaga L; Gil-Gil M; de Quintana-Schmidt C; Valduvieco I; Martinez-Cardús A; Bellosillo B; Muñoz-Marmol AM; Esteve A; Domenech M; Camins A; Craven-Bartle J; Villa S; Marruecos J; Domenech S; de la Iglesia N; Balana C
    Clin Cancer Res; 2021 Jan; 27(2):645-655. PubMed ID: 33106291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs involved in the EGFR pathway in glioblastoma.
    Xu B; Mei J; Ji W; Huo Z; Bian Z; Jiao J; Li X; Sun J; Shao J
    Biomed Pharmacother; 2021 Feb; 134():111115. PubMed ID: 33341046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
    Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
    Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
    [No Abstract]   [Full Text] [Related]  

  • 18. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
    Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A
    J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts.
    Umehara T; Arita H; Yoshioka E; Shofuda T; Kanematsu D; Kinoshita M; Kodama Y; Mano M; Kagawa N; Fujimoto Y; Okita Y; Nonaka M; Nakajo K; Uda T; Tsuyuguchi N; Fukai J; Fujita K; Sakamoto D; Mori K; Kishima H; Kanemura Y
    Acta Neuropathol Commun; 2019 Jun; 7(1):99. PubMed ID: 31215469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZWINT: A potential therapeutic biomarker in patients with glioblastoma correlates with cell proliferation and invasion.
    Yang L; Han N; Zhang X; Zhou Y; Chen R; Zhang M
    Oncol Rep; 2020 Jun; 43(6):1831-1844. PubMed ID: 32323832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.